Michael Xu

804 total citations
12 papers, 292 citations indexed

About

Michael Xu is a scholar working on Molecular Biology, Ecology and Oncology. According to data from OpenAlex, Michael Xu has authored 12 papers receiving a total of 292 indexed citations (citations by other indexed papers that have themselves been cited), including 7 papers in Molecular Biology, 3 papers in Ecology and 2 papers in Oncology. Recurrent topics in Michael Xu's work include Bacteriophages and microbial interactions (3 papers), CRISPR and Genetic Engineering (2 papers) and CAR-T cell therapy research (2 papers). Michael Xu is often cited by papers focused on Bacteriophages and microbial interactions (3 papers), CRISPR and Genetic Engineering (2 papers) and CAR-T cell therapy research (2 papers). Michael Xu collaborates with scholars based in United States, Germany and Singapore. Michael Xu's co-authors include Jennifer A. Doudna, Junjie Liu, Shuang-yong Xu, Ivan R. Corrêa, Yan Ma, Fuguo Jiang, Beatriz A. Osuna, Zhijun Liu, Benjamin J. Rauch and Joel Berry and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Molecular Cell.

In The Last Decade

Michael Xu

11 papers receiving 283 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Michael Xu United States	8	159	53	44	43	24	12	292
Inês Brás Marques Portugal	10	32 0.2×	24 0.5×	32 0.7×	46 1.1×		30	289
Bill Chan Hong Kong	11	149 0.9×	8 0.2×	35 0.8×	12 0.3×		17	411
Stacey Lee United States	12	82 0.5×	9 0.2×	20 0.5×	14 0.3×		23	344
Aintzane Urbizu Spain	13	71 0.4×	14 0.3×	13 0.3×	20 0.5×		23	477
Jivan Shakya Nepal	7	49 0.3×	29 0.5×	30 0.7×	52 1.2×		13	254
Alejandro Luján Feliu‐Pascual United Kingdom	12	41 0.3×	9 0.2×	23 0.5×	72 1.7×		29	344
Héléna Brunel France	11	80 0.5×	10 0.2×	19 0.4×	11 0.3×		27	342
Suk-Chun Mak Taiwan	9	209 1.3×	12 0.2×	23 0.5×	15 0.3×		34	329
Emma Carter United Kingdom	6	86 0.5×	8 0.2×	12 0.3×	35 0.8×		8	199
Rajvinder Karda United Kingdom	10	145 0.9×	4 0.1×	62 1.4×	26 0.6×	3 0.1×	21	289

Countries citing papers authored by Michael Xu

Since Specialization

Citations

This map shows the geographic impact of Michael Xu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Michael Xu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Michael Xu more than expected).

Fields of papers citing papers by Michael Xu

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Michael Xu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Michael Xu. The network helps show where Michael Xu may publish in the future.

Co-authorship network of co-authors of Michael Xu

This figure shows the co-authorship network connecting the top 25 collaborators of Michael Xu. A scholar is included among the top collaborators of Michael Xu based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Michael Xu. Michael Xu is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

12 of 12 papers shown

1.

Xu, Michael, et al.. (2025). Immunotherapy for precision medicine in colorectal cancer. Expert Review of Precision Medicine and Drug Development. 10(1). 16–33.

2.

Xu, Michael, Shijia Chen, Que Liu, et al.. (2023). Preclinical characterization of HPG7233, a potent, liver-target and highly selective thyroid hormone receptor beta agonist for non-alcoholic steatohepatitis. Journal of Hepatology. 78. S784–S784. 1 indexed citations

3.

Xu, Michael, et al.. (2023). Association between bispecific T cell engager (BiTE) therapy and inflammatory adverse effects (AEs) in patients with metastatic castration-resistant prostate cancer (mCRPC).. Journal of Clinical Oncology. 41(16_suppl). e14534–e14534. 1 indexed citations

4.

Xu, Michael, Fabio Quaglia, Li Li, et al.. (2022). STEAP1–4 (Six-Transmembrane Epithelial Antigen of the Prostate 1–4) and Their Clinical Implications for Prostate Cancer. Cancers. 14(16). 4034–4034. 30 indexed citations

5.

Zhang, Shuo, Michael Xu, Zhijun Liu, Juan Feng, & Yan Ma. (2020). Neuropsychiatric issues after stroke: Clinical significance and therapeutic implications. World Journal of Psychiatry. 10(6). 125–138. 35 indexed citations

6.

Knott, Gavin J., Brady F. Cress, Junjie Liu, et al.. (2019). Structural basis for AcrVA4 inhibition of specific CRISPR-Cas12a. eLife. 8. 47 indexed citations

7.

Xu, Michael, Ivan R. Corrêa, Yan‐Jiun Lee, et al.. (2019). Type II Restriction of Bacteriophage DNA With 5hmdU-Derived Base Modifications. Frontiers in Microbiology. 10. 584–584. 20 indexed citations

8.

Jiang, Fuguo, Junjie Liu, Beatriz A. Osuna, et al.. (2018). Temperature-Responsive Competitive Inhibition of CRISPR-Cas9. Molecular Cell. 73(3). 601–610.e5. 62 indexed citations

9.

Xu, Michael. (2018). Poststroke seizure: optimising its management. Stroke and Vascular Neurology. 4(1). 48–56. 53 indexed citations

10.

Corrêa, Ivan R., et al.. (2017). Restriction and modification of deoxyarchaeosine (dG+)-containing phage 9 g DNA. Scientific Reports. 7(1). 8348–8348. 28 indexed citations

11.

Dogan, Yildirim, et al.. (2011). The Nup98-HoxA9 Leukemogenic Fusion Protein Blocks Xpo1 and Tap-Mediated Nuclear Export. Blood. 118(21). 5228–5228. 1 indexed citations

12.

Xu, Michael, et al.. (2007). MR spectroscopy in sinus mucocele: N-acetyl mimics of brain N-acetylaspartate.. American Journal of Neuroradiology. 27(10). 2210–3. 14 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact